Clinical Trial Update: GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 trial of GCAR1 CAR T-cell therapy for GPNMB-expressing solid tumors; study targets alveolar soft-part sarcoma, renal cell carcinoma, and triple-negative…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Renal Cell Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• GCAR1

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING